TargEDys® announces the successful completion of its 3 months, randomized, double blind, placebo-controlled, multicentric clinical study carried out on 229 subjects and evaluating the efficacy of Hafnia alvei HA4597™ in the weight loss by regulation […]
MaaT Pharma announced today an €18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Crédit Mutuel Innovation, and Biocodex. The funding will enable […]
Arranta Bio (“Arranta”), the leading microbiome contract development and manufacturing organization (CDMO), announced today the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as […]
A new collaborative study published by a research team from the Wayne State University School of Medicine, the CReATe Fertility Centre and the University of Massachusetts Amherst provides the first in-depth look at the microbiome […]
A completely new kind of bioreactor for the biological production of methane has enabled the use of extremely high pressure levels for the first time – and set new efficiency standards for the conversion of […]
Kintai Therapeutics, a Flagship Pioneering company, today announced the advancement of KTX-0200, a novel oral anti-obesity agent, into IND-enabling studies following the demonstration of sustained weight loss and improved markers of health in preclinical studies. Treatment […]
Bloom Science, a biopharmaceutical company focused on the discovery and development of precision living medicines for currently untreatable neurological diseases, today announced signing of an agreement with Duke University, granting the Company an option to […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for […]
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces a collaboration with CosmosID to help advance understanding of microbiome complexity in different biological samples and environments. “Our fellow […]
Bayer and Azitra Inc., a clinical-stage medical dermatology biotech company, today announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. The partnership will leverage Azitra’s proprietary panel of […]
Locus Biosciences announced today that it has opened for enrollment a Phase 1b clinical trial evaluating LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli (E. coli) bacteria causing urinary tract infections […]